Scholar Rock - SRRK Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.00
  • Forecasted Upside: 234.62 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$7.77
▲ +0.18 (2.37%)

This chart shows the closing price for SRRK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Scholar Rock Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRRK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRRK

Analyst Price Target is $26.00
▲ +234.62% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Scholar Rock in the last 3 months. The average price target is $26.00, with a high forecast of $33.00 and a low forecast of $19.00. The average price target represents a 234.62% upside from the last price of $7.77.

This chart shows the closing price for SRRK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Scholar Rock. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/18/2022JPMorgan Chase & Co.Lower TargetOverweight$38.00 ➝ $20.00Low
11/15/2022BMO Capital MarketsLower TargetOutperform$43.00 ➝ $32.00Low
9/19/2022HC WainwrightReiterated RatingBuy$30.00Low
8/9/2022BMO Capital MarketsLower Target$55.00 ➝ $43.00Low
7/12/2022Truist FinancialInitiated CoverageBuy$20.00N/A
6/23/2022Piper SandlerLower TargetOverweight$28.00 ➝ $19.00Low
5/24/2022JPMorgan Chase & Co.Lower Target$46.00 ➝ $37.00Low
5/17/2022WedbushLower TargetNA$50.00 ➝ $33.00Low
5/17/2022BMO Capital MarketsLower Target$74.00 ➝ $55.00High
5/16/2022Piper SandlerLower TargetOverweight$56.00 ➝ $28.00N/A
3/23/2022HC WainwrightInitiated CoverageBuy$24.00High
3/7/2022WedbushReiterated RatingOutperform$50.00High
12/22/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$52.00 ➝ $28.00High
11/18/2021Piper SandlerInitiated CoverageOverweight$56.00Low
1/25/2021BMO Capital MarketsBoost TargetPositive ➝ Outperform$54.00 ➝ $79.00High
1/21/2021WedbushBoost TargetOutperform$47.00 ➝ $66.00Medium
1/11/2021Credit Suisse GroupInitiated CoverageOutperform$65.00Medium
1/6/2021JPMorgan Chase & Co.Initiated CoverageOverweight$59.00N/A
11/10/2020WedbushBoost TargetPositive ➝ Outperform$33.00 ➝ $47.00Low
10/28/2020BMO Capital MarketsBoost TargetPositive ➝ Outperform$33.00 ➝ $52.00High
10/27/2020Robert W. BairdReiterated RatingOutperform$35.00 ➝ $39.00High
6/29/2020BMO Capital MarketsReiterated RatingBuy$33.00Low
3/11/2020Robert W. BairdInitiated CoverageOutperform$35.00Medium
11/19/2019CowenReiterated RatingBuyLow
5/15/2019WedbushReiterated RatingOutperform$27.00High
2/27/2019CowenReiterated RatingBuyMedium
11/12/2018CowenReiterated RatingBuyMedium
11/9/2018WedbushReiterated RatingOutperform$25.00Low
6/18/2018CowenInitiated CoverageOutperformHigh
6/18/2018BMO Capital MarketsInitiated CoverageOutperform$31.00High
6/18/2018WedbushInitiated CoverageOutperform$25.00High
6/18/2018Jefferies Financial GroupInitiated CoverageBuy$26.00High
(Data available from 12/1/2017 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/5/2022
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/4/2022
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/4/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/3/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/2/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/2/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/1/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/1/2022

Current Sentiment

  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Scholar Rock logo
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $7.77
Low: $7.34
High: $7.92

50 Day Range

MA: $7.87
Low: $6.45
High: $9.76

52 Week Range

Now: $7.77
Low: $4.32
High: $28.08

Volume

114,576 shs

Average Volume

593,446 shs

Market Capitalization

$401.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Scholar Rock?

The following Wall Street research analysts have issued research reports on Scholar Rock in the last twelve months: BMO Capital Markets, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler, Truist Financial Co., and Wedbush.
View the latest analyst ratings for SRRK.

What is the current price target for Scholar Rock?

7 Wall Street analysts have set twelve-month price targets for Scholar Rock in the last year. Their average twelve-month price target is $26.00, suggesting a possible upside of 234.6%. Wedbush has the highest price target set, predicting SRRK will reach $33.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $19.00 for Scholar Rock in the next year.
View the latest price targets for SRRK.

What is the current consensus analyst rating for Scholar Rock?

Scholar Rock currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRRK will outperform the market and that investors should add to their positions of Scholar Rock.
View the latest ratings for SRRK.

What other companies compete with Scholar Rock?

How do I contact Scholar Rock's investor relations team?

Scholar Rock's physical mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company's listed phone number is (857) 259-3860 and its investor relations email address is [email protected] The official website for Scholar Rock is www.scholarrock.com. Learn More about contacing Scholar Rock investor relations.